Financial Results: Page 2

Hologic fiscal Q1 diagnostics revenues drop 27% on lower demand for COVID testing

Stephen MacMillan, Hologic chairman, president, and CEO, said he believes that the firm is well positioned for long-term growth while COVID testing declines.

February 2, 2023

Roche reports flat diagnostics revenue growth for 2022

For COVID-19 tests, Roche booked 2022 revenues of 4.1 billion Swiss francs, down 13% compared to 4.7 billion Swiss francs in 2021. Revenue growth for its base diagnostics business offset the decline.

February 2, 2023

Abbott CEO expects high single-digit sales growth excluding COVID-19 revenues in 2023

The firm booked diagnostics segment revenues of $3.31 billion in the fourth quarter, down 26.1% year over year. Nonetheless, its CEO sees some easing of macroenvironment challenges that impacted growth in 2022.

January 25, 2023

After Illumina presentation highlighting Grail potential comes a possible EU fine

At the J.P. Morgan healthcare event this week, Illumina's CEO said Grail must be operated separately and independently pursuant to measures required by the EU.

January 12, 2023

Exact Sciences preliminary Q4 revenues rise 16% on strong screening sales

The firm expects screening revenue of $401.8 million to $402.8 million, an increase of 45% year-over-year. The screening business includes laboratory service revenue from Cologuard tests.

January 9, 2023

QuidelOrtho expects Q4 revenues between $853 million and $868 million

Its CEO said QuidelOrtho's strong positioning in the point-of-care market enabled it to serve patients in a strong respiratory season, which drove substantial revenue growth.

January 6, 2023

Most Popular

Ohio, Kentucky doctors convicted in scheme to bill Medicaid for unnecessary urinalysis testing

Simple blood test can detect PTSD biomarkers

Rapid nirmatrelvir treatment in study reduced long-COVID risk

Illumina NGS software to enable tertiary analysis for oncology, rare disease

AmoyDx PLC Panel gets Japanese approval as companion diagnostic for NSCLC

Serum protein in study predicted which patients might die without a liver transplant

Hologic Q1 preliminary revenues drop 27% on COVID decline, beat guidance and analyst estimates

The preliminary revenues are higher than the firm’s recent guidance of $940 million to $990 million and exceed analysts’ average estimate of $966.4 million.

January 9, 2023

Molecular diagnostic firm Biocept to reduce staff by about 35% in restructuring

The San Diego-based company is implementing a restructuring plan that includes reducing staff in connection with the evaluation of strategic alternatives.

January 6, 2023

Meridian Bioscience Q4 revenues drop 14% on lower COVID-19 testing, misses analysts' estimates

Diagnostics segment revenue growth was driven by nonmolecular assay products, which increased 22%.

November 22, 2022

Agilent Technologies Q4 revenues rise 11%

The Diagnostics and Genomics Group generated fourth-quarter revenue of $352 million, up 3% year-over-year.

November 21, 2022

Twist Bioscience Q4 revenues rise 51%

Among its recent business highlights, the firm noted that it collaborated with PacBio to develop an initial portfolio of off-the-shelf long-read gene panels, including a 50-gene pharmacogenomics panel.

November 18, 2022

Siemens Healthineers Q4 Dx revenues rise 13% on increased sales of COVID-19 rapid antigen tests

In the recently completed quarter, Siemens Healthineers booked €232 million from COVID-19 rapid antigen tests compared to around €160 million in Q4 2021.

November 9, 2022

Previous Page

Page 2 of 10

Next Page